EQUITY RESEARCH MEMO

Dot Decimal

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)75/100

Dot Decimal is a precision manufacturer and software developer that produces patient-specific, custom beam-shaping devices for radiation therapy. Founded in 2015 and based in Raleigh, the company serves over 900 clinics across the United States, providing on-demand devices for proton, electron, and photon treatments. Its integrated approach combines physical device manufacturing with proprietary software for treatment planning and quality assurance, enabling personalized cancer care. By addressing the growing demand for precision radiotherapy, Dot Decimal occupies a niche but critical role in the oncology treatment chain, with potential for expansion as radiation therapy becomes more advanced and personalized.

Upcoming Catalysts (preview)

  • Q4 2026Expansion of clinic partnerships and geographic reach80% success
  • Q2 2026Release of next-generation treatment planning software65% success
  • TBDStrategic collaboration or acquisition by a larger radiation therapy equipment manufacturer30% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)